Diffuse Large B Cell Lymphoma: Changing Landscapes of Treatment Strategy and the Aspirations in 2024

Amin Islam(1), Sumeet Gujral(2), Tim Farren(3), Marianne Grantham(4)
(1) Queen Mary University, London, United Kingdom
(2) Tata Memorial Hospital, Mumbai, India
(3) Barts Health NHS Trust, United Kingdom
(4) Barts Health NHS Trust, United Kingdom

Abstract

Diffuse large B-cell lymphoma (DLBCL) represents the commonest subtype of non-Hodgkin lymphoma, encompasses a group of diverse disease entities, each harbouring unique molecular and clinico-pathological feature. The understanding of the molecular landscape of DLBCL has improved significantly over the past decade, highlighting unique genomic subtypes with implications on targeted therapy. At the same time, several new treatment modalities have been recently approved both in the frontline and relapsed settings, ending a dearth of negative clinical trials that plagued the past decade. Despite that, in the real-world setting, issues like drug accessibility, reimbursement policies, physician and patient preference, as well as questions regarding optimal sequencing of treatment options present difficulties and challenges in day-to-day haemato-oncology practice. Here, we review the recent advances in the therapeutic armamentarium of DLBCL and discuss implications on the practice landscape. Diffuse large B-cell lymphoma (DLBCL) is usually treated with chemoimmunotherapy in curative intention at initial diagnosis. Novel agents have improved the prognosis of high-risk patients in the front-line and relapsed setting and more accurate prognostic tools enable less intensive treatment for low-risk patients, while maintaining their good prognosis. Here, we summarise our approach to DLBCL patients in the first line setting according to their risk profile and other common challenges in clinical practice. We recommend an abbreviated course of chemoimmunotherapy in low-risk patients and a negative interim positron emission tomography. For patients with higher-risk disease, a new combination treatment with polatuzumab vedotin has been approved and is a new option in these patients. We also discuss our approach to patients with high risk for subsequent central nervous system involvement, with leg-type lymphoma or with severe comorbidities which we encounter frequently in our daily clinical practices.

Full text article

Generated from XML file

References

Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haema-tolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–48. https://doi.org/10.1038/s41375-022-01620-2.

Campo E, Jaffe ES, Cook JR, et al. The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood. 2022;140(11):1229–53. https://doi.org/10.1182/blood.2022015851.

Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333(23):1540–5. https://doi.org/10.1056/NEJM199512073332305.

Crump M, Neelapu SS, Farooq U et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017 Oct 19; 130(16): 1800–1808. doi: https://doi.org/10.1182/blood-2017-03-769620. Epub 2017 Aug 3. Erratum in: Blood. 2018 Feb 1; 131(5): 587–588. PMID: 28774879; PMCID: PMC5649550.

Nastoupil LJ, Bartlett NL. Navigating the evolving treatment landscape of diffuse large B-cell lymphoma. J Clin Oncol. 2023;41(4):903–13. https://doi.org/10.1200/JCO.22.01848.

Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384(9):842–58. https://doi.org/10.1056/NEJMra2027612.

Lim RB, Loy EY, Lim GH, Zheng H, Chow KY, Lim ST. Gender and ethnic differences in incidence and survival of lymphoid neoplasm subtypes in an Asian population: secular trends of a population-based cancer registry from 1998 to 2012. Int J Cancer. 2015;137(11):2674–87. https://doi.org/10.1002/ijc.29635.

Ngo L, Hee SW, Lim LC, et al. Prognostic factors in patients with diffuse large B cell lymphoma: before and after the intro-duction of rituximab. Leuk Lymphoma. 2008;49(3):462–9. https://doi.org/10.1080/10428190701809156.

Schmitz N, Zeynalova S, Nickelsen M, et al. CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2016;34(26):3150-3156.

Hutchings M, Ladetto M, Buske C, et al. ESMO Consensus Conference on malignant lymphoma: management of ‘ul-tra-high-risk’ patients. Ann Oncol. 2018;29(8):1687-1700.

Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Hae-matolymphoid Tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720-1748.

Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–42.

Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-985 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116(12):2040–5.

Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M, MabThera International Trial Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised con-trolled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379–91.

Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105–16.

Récher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet. 2011;378(9806):1858–67.

Bartlett NL, Wilson WH, Jung SH, et al. Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-Cell lymphoma: clinical outcomes of the phase III intergroup trial alliance/CALGB 50303. J Clin Oncol. 2019;37(21):1790–9.

Stiff PJ, Unger JM, Cook JR, et al. Autologous transplantation as consolidation for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 2013;369(18):1681–90.

Seymour JF, Pfreundschuh M, Trn?ný M, et al. R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes. Haematologica. 2014;99(8):1343–9.

Vitolo U, Trn?ný M, Belada D, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-Cell lymphoma. J Clin Oncol. 2017;35(31):3529–37. https://doi.org/10.1200/JCO.2017.73.3402.

Nowakowski GS, Chiappella A, Gascoyne RD, et al. ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma. J Clin Oncol. 2021;39(12):1317–28. https://doi.org/10.1200/JCO.20.01366.

Younes A, Sehn LH, Johnson P, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-Cell lymphoma. J Clin Oncol. 2019;37(15):1285–95. https://doi.org/10.1200/JCO.18.02403.

Thieblemont C, Tilly H, Gomes da Silva M, et al. Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large b-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2017;35(22):2473–81. https://doi.org/10.1200/JCO.2017.72.6984.

Dornan D, Bennett F, Chen Y, et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood. 2009;114(13):2721–9. https://doi.org/10.1182/blood-2009-02-205500.

Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386(4):351–63. https://doi.org/10.1056/NEJMoa2115304.

Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma Published: 01 March 2023. https://www.nice.org.uk/guidance/ta874. Accessed 4 Apr 2023.

Oncologic Drugs Advisory Committee (ODAC) Meeting. FDA website. March 9, 2023. https://www.fda.gov/advisory-committees/advisory-committee-calendar/march-9-2023-meeting-oncologic-drugs-advisory-committee-meeting-announcement-03092023. Accessed 4 Apr 2023.

Hawkes EA, Barraclough A, Sehn LH. Limited-stage diffuse large B-cell lymphoma. Blood. 2022;139(6):822–34. https://doi.org/10.1182/blood.2021013998.

Ziepert M, Hasenclever D, Kuhnt E et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010 May 10; 28(14): 2373–80. doi: https://doi.org/10.1200/JCO.2009.26.2493. Epub 2010 Apr 12. Erratum in: J Clin Oncol. 2011 Feb 20; 29(6): 779. PMID: 20385988.

Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med. 1998;339(1):21–6. https://doi.org/10.1056/NEJM199807023390104

Rojek AE, Smith SM. Evolution of therapy for limited stage diffuse large B-cell lymphoma. Blood Cancer J. 2022;12(2):33. https://doi.org/10.1038/s41408-021-00596-z.

Poeschel V, Held G, Ziepert M, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 2019;394(10216):2271–81. https://doi.org/10.1016/S0140-6736(19)33008-9.

Persky DO, Li H, Stephens DM et al. positron emission tomography-directed therapy for patients with limited-stage diffuse large B-cell lymphoma: results of intergroup national clinical trials network study S1001. J Clin Oncol. 2020 Sep 10; 38(26): 3003–3011. doi: https://doi.org/10.1200/JCO.20.00999. Epub 2020 Jul 13. Erratum in: J Clin Oncol. 2020 Oct 10; 38(29): 3459. PMID: 32658627; PMCID: PMC7479758.

Bologna S. Early positron emission tomography response-adapted treatment in localized diffuse large B-cell lymphoma (aaIPI=0): results of the phase 3 LYSA LNH 09–1B trial. Hematol Oncol. 2021. https://doi.org/10.1002/hon.5_2879.

Scott DW, Mottok A, Ennishi D, et al. Prognostic significance of diffuse large B-Cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J Clin Oncol. 2015;33(26):2848–56. https://doi.org/10.1200/JCO.2014.60.2383.

Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–82. https://doi.org/10.1182/blood-2003-05-1545.

Rosenwald A, Bens S, Advani R, et al. Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the lunenburg lymphoma biomarker consortium. J Clin Oncol. 2019;37(35):3359–68. https://doi.org/10.1200/JCO.19.00743.

Scott DW, King RL, Staiger AM, et al. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood. 2018;131(18):2060–4. https://doi.org/10.1182/blood-2017-12-820605.

Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124(15):2354–61. https://doi.org/10.1182/blood-2014-05-578963.

Molina TJ, Canioni D, Copie-Bergman C, et al. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d’Etudes des Lymphomes de l’Adulte/lymphoma study association phase III trial LNH 03–2B. J Clin Oncol. 2014;32(35):3996–4003. https://doi.org/10.1200/JCO.2013.54.9493.

Dodero A, Guidetti A, Tucci A, et al. Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma. Leukemia. 2019;33(4):1047–51. https://doi.org/10.1038/s41375-018-0320-9.

Dunleavy K, Fanale MA, Abramson JS, et al. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Lancet Haematol. 2018;5(12):e609–17. https://doi.org/10.1016/S2352-3026(18)30177-7.

Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011;12(5):460–8. https://doi.org/10.1016/S1470-2045(11)70069-9.

Oberic L, Peyrade F, Puyade M, et al. Subcutaneous Rituximab-MiniCHOP compared with subcutaneous Rituxi-mab-MiniCHOP plus lenalidomide in diffuse large B-cell lymphoma for patients age 80 years or older. J Clin Oncol. 2021;39(11):1203–13. https://doi.org/10.1200/JCO.20.02666.

Xu PP, Shi ZY, Qian Y, Cheng S, Zhu Y, Jiang L, Li JF, Fang H, Huang HY, Yi HM, Ouyang BS, Wang L, Zhao WL. Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study. Lancet Healthy Longev. 2022;3(7):e481–90. https://doi.org/10.1016/S2666-7568(22)00123-4.

Rieger M, Osterborg A, Pettengell R, et al. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol. 2011;22(3):664–70.

Shah NN, Szabo A, Huntington SF et al. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary me-diastinal B-cell lymphoma: a multi-centre analysis. Br J Haematol. 2018 Feb; 180(4): 534–544. doi:

Vitolo U, Chiappella A, Ferreri AJ, et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol. 2011;29(20):2766–72. https://doi.org/10.1200/JCO.2010.31.4187.

Barta SK, Lee JY, Kaplan LD, Noy A, Sparano JA. Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma. Cancer. 2012;118(16):3977–83. https://doi.org/10.1002/cncr.26723

Barta SK, Xue X, Wang D, et al. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood. 2013;122(19):3251–62. https://doi.org/10.1182/blood-2013-04-498964.

Sparano JA, Lee JY, Kaplan LD, et al. Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin’s lymphoma. Haematologica. 2021;106(3):730–5. https://doi.org/10.3324/haematol.2019.243386.

Wilson MR, Bobillo S, Cwynarski K. CNS prophylaxis in aggressive B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2022;2022(1):138–45. https://doi.org/10.1182/hematology.2022000331

Schmitz N, Zeynalova S, Nickelsen M, et al. CNS International prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2016;34(26):3150–6. https://doi.org/10.1200/JCO.2015.65.6520.

Eyre TA, Djebbari F, Kirkwood AA, Collins GP. Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review. Haematologica. 2020;105(7):1914–24. https://doi.org/10.3324/haematol.2019.229948.

Lin Z, Chen X, Liu L, Zeng H, Li Z, Xu B. The role of central nervous system (CNS) prophylaxis in preventing DLBCL patients from CNS relapse: a network meta-analysis. Crit Rev Oncol Hematol. 2022;176:103756. https://doi.org/10.1016/j.critrevonc.2022.103756.

Nuvvula S, Dahiya S, Patel SA. The novel therapeutic landscape for relapsed/refractory diffuse large B cell lymphoma. Clin Lymphoma Myeloma Leuk. 2022;22(6):362–72. https://doi.org/10.1016/j.clml.2021.11.010.

Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and re-fractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014;32(31):3490–6. https://doi.org/10.1200/JCO.2013.53.9593.

Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–44. https://doi.org/10.1056/NEJMoa1707447.

Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56. https://doi.org/10.1056/NEJMoa1804980.

Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–52. https://doi.org/10.1016/S0140-6736(20)31366-0.

Kamdar M, Solomon SR, Arnason J et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy fol-lowed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022 Jun 18; 399(10343): 2294-2308. doi: https://doi.org/10.1016/S0140-6736(22)00662-

Westin JR, Oluwole OO, Kersten MJ, et al. Survival with axicabtagene ciloleucel in Large B-cell lymphoma. N Engl J Med. 2023. https://doi.org/10.1056/NEJMoa2301665.

Sehn LH, Hertzberg M, Opat S, et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. Blood Adv. 2022;6(2):533–43. https://doi.org/10.1182/bloodadvances.2021005794.

Salles G, Duell J, González Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lym-phoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21(7):978–88. https://doi.org/10.1016/S1470-2045(20)30225-4.

Herrera AF, Chen L, Crombie JL, et al. Polatuzumab vedotin combined with R-ICE (PolaR-ICE) as second-line therapy in relapsed/refractory diffuse large B-cell lymphoma. Blood. 2022;140(Supplement 1):1065–7. https://doi.org/10.1182/blood-2022-165699.

Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022;387(24):2220–31. https://doi.org/10.1056/NEJMoa2206913.

Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial. J Clin Oncol. 2022;22:2201725. https://doi.org/10.1200/JCO.22.01725.

Bannerji R, Arnason JE, Advani RH, et al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022;9(5):e327–39. https://doi.org/10.1016/S2352-3026(22)00072-2.Return to ref 135 in article

FDA website. June 15, 2023. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-glofitamab-gxbm-selected-relapsed-or-refractory-large-b-cell. Accessed 26 June 2023.

Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 May; 24(5): 679–690. doi: https://doi.org/10.1038/s41591-018-0016-8.

Wright GW, Huang DW, Phelan JD, et al. A Probabilistic classification tool for genetic subtypes of diffuse large b cell lym-phoma with therapeutic implications. Cancer Cell. 2020;37(4):551-568.e14. https://doi.org/10.1016/j.ccell.2020.03.015.

Lacy SE, Barrans SL, Beer PA, et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a haematological malignancy research network report. Blood. 2020;135(20):1759–71. https://doi.org/10.1182/blood.2019003535.

Lee JY, Kannan B, Lim BY, et al. The multi-dimensional biomarker landscape in cancer immunotherapy. Int J Mol Sci. 2022;23(14):7839. https://doi.org/10.3390/ijms23147839.

Authors

Amin Islam
amin.islam2@nhs.net (Primary Contact)
Sumeet Gujral
Tim Farren
Marianne Grantham
Author Biographies

Amin Islam, Queen Mary University, London

Senior Consultant Haematologist and BMT Physician, Mid and South Essex Hospitals NHS Foundation Trusts, Hon Senior Clinical Lecturer in Haematology, Queen Mary University, London

Sumeet Gujral, Tata Memorial Hospital, Mumbai

Professor and Director of Pathology, Tata Memorial Hospital, Mumbai, India

Tim Farren, Barts Health NHS Trust

Barts and The London School of Medicine and Dentistry, Queen Mary University of London

Marianne Grantham, Barts Health NHS Trust

Barts and The London School of Medicine and Dentistry, Queen Mary University of London

1.
Islam A, Gujral S, Farren T, Grantham M. Diffuse Large B Cell Lymphoma: Changing Landscapes of Treatment Strategy and the Aspirations in 2024. Haematol J Bangladesh [Internet]. 2023 Dec. 31 [cited 2024 Apr. 17];7(2):99-114. Available from: https://journal.hematologybd.org/index.php/haematoljbd/article/view/122

Article Details

How to Cite

1.
Islam A, Gujral S, Farren T, Grantham M. Diffuse Large B Cell Lymphoma: Changing Landscapes of Treatment Strategy and the Aspirations in 2024. Haematol J Bangladesh [Internet]. 2023 Dec. 31 [cited 2024 Apr. 17];7(2):99-114. Available from: https://journal.hematologybd.org/index.php/haematoljbd/article/view/122